^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    4d
    Association of CDKN2A/B Homozygous Deletion and Extent of Resection With Survival of Patients With WHO CNS5 Grade 4 Astrocytoma. (PubMed, Ann Clin Transl Neurol)
    Histologic grade 4 astrocytomas with CDKN2A/B homozygous deletion confer the worst survival. Maximal or complete resection, as assessed on FLAIR images, is critical to improving outcomes.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion
    5d
    An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma (clinicaltrials.gov)
    P2, N=25, Recruiting, Mayo Clinic | Trial completion date: Apr 2026 --> Jul 2028 | Trial primary completion date: Apr 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    7d
    Differential diagnosis of high-grade astrocytic gliomas based on CD44, SOX2, and CIRBP gene expression analysis (PubMed, Zh Vopr Neirokhir Im N N Burdenko)
    Original method based on marker gene expression ratios does not replace standard diagnostic protocols, but may be an additional tool for optimized diagnostic process. This approach will be valuable to minimize errors and personalize therapeutic strategies. The last one is critical for prognosis.
    Journal
    |
    SOX2
    |
    IDH wild-type
    14d
    A Rare Association of Reactive Retinal Astrocytic Tumor With Chronic Rhegmatogenous Retinal Detachment. (PubMed, Retin Cases Brief Rep)
    This report describes a rare association between occult RRAT and chronic RRD in an elderly patient. Histopathologic examination of such tumors is essential for accurate diagnosis while surgical management must be tailored to tumor size, location, and associated complications.
    Journal
    |
    CD163 (CD163 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • GFAP (Glial Fibrillary Acidic Protein)
    17d
    A congenital infant-type hemispheric glioma case with EML4::ALK fusion. (PubMed, Childs Nerv Syst)
    She is now 7 years old and doing well with no recurrence. To our knowledge, this is the first report of a congenital intraventricular tumor with EML4::ALK fusion.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ALK fusion
    19d
    Noninvasive MGMT-promotor methylation prediction in high grade gliomas using conventional MRI and deep learning-based segmentations. (PubMed, Front Neurosci)
    Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter in HGG is crucial for temozolomide efficacy...MGMTpm status and region of interest volumes impact OS and PFS. Future studies should incorporate other molecular imaging sequences for methylation prediction.
    Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation
    |
    temozolomide
    24d
    Staining the Invisible: Immunohistochemistry for Early Detection of Mismatch Repair Deficiency in Pediatric High-Grade Brain Tumors. (PubMed, Pediatr Blood Cancer)
    IHC is a practical, low-cost screening tool, especially in resource-limited settings. Routine IHC for MMR proteins in pediatric high-grade CNS tumors may facilitate early CMMRD detection, optimize treatment, and support genetic counseling.
    Journal • Mismatch repair
    |
    MSH6 (MutS homolog 6)
    26d
    Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial. (PubMed, Lancet Oncol)
    Long-term follow-up confirms that radiotherapy followed by 12 cycles of adjuvant temozolomide without concurrent temozolomide during radiotherapy improves survival for individuals with aggressive IDHmt astrocytoma.
    Clinical • P3 data • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • MGMT (6-O-methylguanine-DNA methyltransferase) • CDK4 (Cyclin-dependent kinase 4)
    |
    CDKN2A deletion • MGMT promoter methylation • IDH wild-type
    |
    temozolomide
    27d
    GI-102 Alone or in Combination With Pembrolizumab Before Surgery for the Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Mayo Clinic
    New P2 trial
    |
    Keytruda (pembrolizumab)
    30d
    WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases (clinicaltrials.gov)
    P1, N=55, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Dec 2030
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR amplification • EGFR L861Q • IDH wild-type
    |
    WSD0922
    1m
    Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Florida | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab)
    1m
    Proton Radiation Therapy for Gliomas (clinicaltrials.gov)
    P=N/A, N=63, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: May 2025 --> May 2027
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation